Proto-oncogene Wnt-3a (WNT3A)

Proto-oncogene Wnt-3a (WNT3A) is a cysteine-rich, secreted glycoprotein that acts as a key ligand for the canonical Wnt/beta-catenin signaling pathway (UniProt, P56704). It binds to the Frizzled (FZD) family of receptors and the low-density lipoprotein receptor-related protein 5/6 (LRP5/6) co-receptors on the cell surface. This binding event inhibits the "destruction complex," leading to the stabilization and nuclear translocation of beta-catenin, which then modulates the expression of genes involved in cell fate determination and proliferation (PubMed, PMC4972793). WNT3A signaling is vital for normal embryonic development, particularly in body axis formation and limb development, as well as for adult stem cell maintenance in the skin and intestine (NCBI, Gene ID: 89780). In various cancers, including colorectal, breast, and liver cancer, aberrant activation of WNT3A-mediated signaling promotes tumor growth, epithelial-to-mesenchymal transition, and chemoresistance (PubMed, PMC8146377). Pharmacological targeting of this pathway includes the use of Porcupine (PORCN) inhibitors, which prevent the post-translational palmitoylation required for WNT3A secretion, and monoclonal antibodies that block ligand-receptor interactions. However, therapeutic implementation faces challenges due to "on-target" toxicities, such as gastrointestinal distress and bone density loss, stemming from the pathway's role in healthy tissue homeostasis (PubMed, PMC6057794).

Other names

Wnt-3aWingless-type MMTV integration site family member 3AWNT3A proteinProtein Wnt-3a

Inhibition of Porcupine (PORCN) to prevent Wnt palmitoylation and secretion, antagonism of Frizzled receptors to block ligand binding, and stabilization of the beta-catenin destruction complex via Tankyrase inhibition.